NCT02756247View on ClinicalTrials.gov

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 9, 2016

Primary Completion Date

October 6, 2022

Study Completion Date

October 6, 2022

Conditions
LymphomaMantle Cell LymphomaFollicular LymphomaDiffuse Large B Cell Lymphoma
Interventions
DRUG

Buparlisib

DRUG

Ibrutinib

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER